Study S000065

Effect of Pioglitazone With and Without Exenatide on Body Weight, Fat Topography, Beta Cell Function, and Glycemic Control in Type 2 Diabetic Patients

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00845182
Acronym: PIO-EX
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: SINGLE
Status: COMPLETED
Enrollment: 43
Start: 2007-06
Primary completion: 2010-07
Lead sponsor: The University of Texas Health Science Center at San Antonio
Conditions: Type 2 Diabetes; Healthy; Impaired Glucose Tolerance
Interventions: DRUG:Pioglitazone; DRUG:Exenatide; DRUG:Pioglitazone and Exenatide
Results posted: TRUE

Registered primary outcomes

Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight [baseline and 6 months]
HbA1c [baseline and 6 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.